224 related articles for article (PubMed ID: 19667026)
1. Bayesian design using adult data to augment pediatric trials.
Schoenfeld DA; Hui Zheng ; Finkelstein DM
Clin Trials; 2009 Aug; 6(4):297-304. PubMed ID: 19667026
[TBL] [Abstract][Full Text] [Related]
2. Bayesian Design for Pediatric Clinical Trials with Binary Endpoints When Borrowing Historical Information of Treatment Effect.
Jin M; Li Q; Kaur A
Ther Innov Regul Sci; 2021 Mar; 55(2):360-369. PubMed ID: 32955713
[TBL] [Abstract][Full Text] [Related]
3. Alone, together: On the benefits of Bayesian borrowing in a meta-analytic setting.
Harari O; Soltanifar M; Verhoek A; Heeg B
Pharm Stat; 2023; 22(5):903-920. PubMed ID: 37321565
[TBL] [Abstract][Full Text] [Related]
4. Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials.
Sebastien B; Cheung SYA; Corriol-Rohou S; Gamalo-Siebers M; Jreich R; Krishna R; Liu J
J Biopharm Stat; 2023 Nov; 33(6):726-736. PubMed ID: 36524777
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian approach in design and analysis of pediatric cancer clinical trials.
Ye J; Reaman G; De Claro RA; Sridhara R
Pharm Stat; 2020 Nov; 19(6):814-826. PubMed ID: 32537913
[TBL] [Abstract][Full Text] [Related]
6. Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development.
Wu Y; Hui J; Deng Q
Pharm Stat; 2020 Nov; 19(6):787-802. PubMed ID: 32573051
[TBL] [Abstract][Full Text] [Related]
7. Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation.
Gamalo-Siebers M; Savic J; Basu C; Zhao X; Gopalakrishnan M; Gao A; Song G; Baygani S; Thompson L; Xia HA; Price K; Tiwari R; Carlin BP
Pharm Stat; 2017 Jul; 16(4):232-249. PubMed ID: 28448684
[TBL] [Abstract][Full Text] [Related]
8. Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing.
Spanakis E; Kron M; Bereswill M; Mukhopadhyay S
J Biopharm Stat; 2023 Nov; 33(6):752-769. PubMed ID: 36507718
[TBL] [Abstract][Full Text] [Related]
9. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL).
Majumdar A; Rothwell R; Reaman G; Ahlberg C; Roy P
J Biopharm Stat; 2023 Nov; 33(6):737-751. PubMed ID: 36600441
[TBL] [Abstract][Full Text] [Related]
10. Optimal sample size determination for single-arm trials in pediatric and rare populations with Bayesian borrowing.
Ji Z; Lin J; Lin J
J Biopharm Stat; 2022 Jul; 32(4):529-546. PubMed ID: 35604836
[TBL] [Abstract][Full Text] [Related]
11. A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS.
Psioda MA; Xue X
J Biopharm Stat; 2020 Nov; 30(6):1091-1108. PubMed ID: 33019841
[TBL] [Abstract][Full Text] [Related]
12. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
Chu Y; Yuan Y
Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
[TBL] [Abstract][Full Text] [Related]
13. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
14. Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics.
Huff RA; Maca JD; Puri M; Seltzer EW
Pediatr Res; 2017 Nov; 82(5):814-821. PubMed ID: 28700566
[TBL] [Abstract][Full Text] [Related]
15. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
Turner RM; Turkova A; Moore CL; Bamford A; Archary M; Barlow-Mosha LN; Cotton MF; Cressey TR; Kaudha E; Lugemwa A; Lyall H; Mujuru HA; Mulenga V; Musiime V; Rojo P; Tudor-Williams G; Welch SB; Gibb DM; Ford D; White IR;
BMC Med Res Methodol; 2022 Feb; 22(1):49. PubMed ID: 35184739
[TBL] [Abstract][Full Text] [Related]
16. Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes.
Fayette L; Sailer MO; Perez-Pitarch A
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1386-1397. PubMed ID: 37644910
[TBL] [Abstract][Full Text] [Related]
17. A group-sequential randomized trial design utilizing supplemental trial data.
Kotalik A; Vock DM; Hobbs BP; Koopmeiners JS
Stat Med; 2022 Feb; 41(4):698-718. PubMed ID: 34755388
[TBL] [Abstract][Full Text] [Related]
18. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
Feißt M; Krisam J; Kieser M
Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
[TBL] [Abstract][Full Text] [Related]
19. Bayesian methods for the design and interpretation of clinical trials in very rare diseases.
Hampson LV; Whitehead J; Eleftheriou D; Brogan P
Stat Med; 2014 Oct; 33(24):4186-201. PubMed ID: 24957522
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Adult Data in Designing Pediatric Pharmacokinetic Studies: How Much Are Historical Adult Data Worth?
Hsu CH; Steven Xu X; Wang J; Zhang L; Liu C; Wang Y
J Clin Pharmacol; 2019 Jul; 59(7):989-996. PubMed ID: 30748023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
